20. November 2009 02:14
Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced the United States Patent and Trademark Office has allowed multiple claims in one of the company’s recent patent applications. US patent application 12/005653, “Short Bioactive Peptides for Cellular and Immunological Modulation,” covers a number of peptides including Heptapeptide-7, a SmartPeptides™ technology and lead component in the Striking™ Skin Care line. The patent is expected to issue shortly.
[More]
19. November 2009 01:42
Today, Merz Pharmaceuticals announced Xeomin®, the first botulinum toxin type A free from complexing proteins has been granted an extension of indication for post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults in various European countries.
[More]
234d5eb2-35a6-4162-8012-1ce935422d94|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Acne, Alzheimer's Disease, Dermatology, Diarrhea, Dystonia, Headache, Hygiene, Hypercholesterolemia, Hyperglycemia, Neurology, Parkinson's Disease, Podiatry, Stroke, Tinnitus
18. November 2009 04:45
Growing use of lasers in surgical and ophthalmic applications, as well as higher number of cosmetic procedures, continues to drive the medical lasers market. Prospects for laser application in cosmetic skin resurfacing appear all the more brighter with growing desire for 'preservation of youth' among the baby boomer generation.
[More]
18. November 2009 04:03
More than six percent of expectant mothers in Quebec consume prescription drugs that are known to be harmful to their fetuses, according to a Universit- de Montr-al investigation published in the British Journal of Obstetrics and Gynaecology
[More]
16. November 2009 09:21
The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with 1st-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
[More]
f2838858-9c45-4eb8-a649-a6b5654e9bab|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Acne, Antibody, Cancer, Cell, Cetuximab, Chemotherapy, Colorectal Cancer, Endocrinology, Fertility, Glioblastoma, Head and Neck Cancer, Hypersensitivity, Infertility, Irinotecan, Liposome, Lung Cancer, Metformin, Monoclonal Antibody, Multiple Sclerosis, Non-Small Cell Lung Cancer, Oncology, Oxaliplatin, Radiotherapy, Small Cell Lung Cancer, Smoking, Squamous Cell Carcinoma, Vaccine
16. November 2009 07:15
PhotoMedex, Inc. a leading provider of advanced dermatology, clinical skincare and medical laser products, is hosting a free seminar in Indianapolis, IN on November 17, 2009.
[More]
11. November 2009 06:42
Glissandra™ Skincare Inc. today announced the global launch of its three signature anti-aging products concurrent with the Israel Cancer Research Fund’s “Women of Action” awards luncheon honoring Beverly Cohen, Lisi Harrison, and Vivien Zighelboim, Ph.D, at the Four Seasons Hotel, Los Angeles at Beverly Hills.
[More]
11. November 2009 06:33
Sol-Gel Technologies announced today that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Sol-Gel’s Investigational New Drug Application (IND) for DER45-EV Gel for the topical treatment of rosacea. This IND allows Sol-Gel to initiate Phase II studies with DER45-EV Gel in rosacea patients.
[More]
11. November 2009 02:58
Everyone expects their bodies to change as they get older. From wrinkles and sagging skin to brittle bones and aches and pains, the aging process is inevitable. In addition, there are a number of medical dermatologic conditions that surface with age that can cause people even more stress. Fortunately, dermatologists can help diagnose and treat these conditions no matter when they strike.
[More]
d17e4d5a-dfd6-434f-a1b5-a9fb4f708e2c|0|.0
Posted in: Medical Condition News | Healthcare News
Tags: Acne, Alopecia, Anemia, Baldness, Birth Control, Dermatology, Diet, Education, Finasteride, Lupus, Menopause, Metronidazole, Rosacea, Stress, Transplant, Varicose Veins, Zinc, Zinc Oxide
9. November 2009 06:09
Syneron Medical Ltd., an innovator in the development, marketing and sales of elos™ combined-energy medical aesthetic devices, today announced financial results for the third quarter ended September 30, 2009.
[More]
4. November 2009 07:34
Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three and nine months ended September 30, 2009.
[More]
4. November 2009 06:54
The global market for cosmeceuticals (cosmetics offering health benefits) is growing nearly twice as fast as the overall cosmetics and toiletries market. However, in order to sustain such rapid growth, manufacturers and brand owners must fill a relentless demand for new ingredient concepts in a context of changing government regulations, market dynamics and cultural trends.
[More]
4. November 2009 06:33
Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that third quarter consolidated net loss from continuing operations attributable to Safeguard common shareholders was $11.6 million, or $0.57 per share, compared with a net loss of $4.1 million, or $0.20 per share, in the same period of 2008.
[More]
5453c92a-b5f8-46f7-9b54-d7f13d9a2c7d|0|.0
Posted in: Business / Finance
Tags: Acne, Alzheimer's Disease, Biopsy, Bladder Cancer, Bone, Brain, Cancer, Cell, Dermatitis, Dermatology, Diabetes, Hospital, Migraine, Nausea, Orthopedic, Pregnancy, Psoriasis, Renal Failure, Ulcer
3. November 2009 00:57
Cipher Pharmaceuticals Inc. today announced that Purdue Pharma Products L.P. and Napp Pharmaceutical Group Ltd. have filed a complaint against Cipher in the United States District Court for the Eastern District of Virginia, for alleged infringement of two U.S. patents. The action relates to Cipher's New Drug Application ("NDA") filed with the U.S. Food and Drug Administration ("FDA") for CIP TRAMADOL ER, the Company's extended-release tramadol product.
[More]
31. October 2009 01:18
NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.
[More] 
Subscribe